Diagnosis and management options in malignant pleural effusions

Malignant pleural effusion (MPE) denotes an advanced malignant disease process. Most of the MPE are metastatic involvement of the pleura from primary malignancy at lung, breast, and other body sites apart from lymphomas. The diagnosis of MPE has been traditionally made on cytological examination of pleural fluid and/or histological examination of pleural biopsy tissue that still remains the initial approach in these cases. There has been tremendous advancement in the diagnosis of MPE now a day with techniques i.e. characteristic Ultrasound and computed tomography features, image guided biopsies, fluorodeoxyglucose-positron emission tomography imaging, thoracoscopy with direct biopsy under vision, tumor marker studies and immunocytochemical analysis etc., that have made possible an early diagnosis of MPE. The management of MPE still remains a challenge to pulmonologist and oncologist. Despite having various modalities with better tolerance such as pleurodesis and indwelling pleural catheters etc., for long-term control, all the management approaches remain palliative to improve the quality of life and reduce symptoms. While choosing an appropriate management intervention, one should consider the clinical status of the patient, life expectancy, overall cost, availability and comparative institutional outcomes, etc.

[1]  P. Rubin,et al.  The management of pleural effusions and chylothorax in lymphoma. , 1965, Radiology.

[2]  O. Järvi,et al.  The accuracy and significance of cytologic cancer diagnosis of pleural effusions. (A followup study of 338 patients). , 1972, Acta cytologica.

[3]  T B Ferguson,et al.  The treatment of malignant pleural effusions , 1974, Cancer.

[4]  C. Flower,et al.  Ultrasound in the diagnosis and management of pleural disease. , 1980, British journal of diseases of the chest.

[5]  M. Estenne,et al.  Mechanism of relief of dyspnea after thoracocentesis in patients with large pleural effusions. , 1983, The American journal of medicine.

[6]  A. Cantó,et al.  Points to consider when choosing a biopsy method in cases of pleurisy of unknown origin. , 1983, Chest.

[7]  F. Rodríguez‐Panadero,et al.  Low glucose and pH levels in malignant pleural effusions. Diagnostic significance and prognostic value in respect to pleurodesis. , 1989, The American review of respiratory disease.

[8]  C. Henschke,et al.  MR imaging of pleural effusions. , 1990, Journal of computer assisted tomography.

[9]  M. Tattersall,et al.  Management of malignant pleural effusions. , 1990, Thorax.

[10]  C. Bennett,et al.  Treating malignant pleural effusions cost consciously. , 1998, Chest.

[11]  C. Bedrossian Diagnostic problems in serous effusions , 1998, Diagnostic cytopathology.

[12]  J. Herndon,et al.  Cytologically proved malignant pleural effusions: distribution of transudates and exudates. , 1998, Chest.

[13]  A. Musk,et al.  Management of malignant pleural mesothelioma: a critical review , 2000, Current opinion in pulmonary medicine.

[14]  F. Gleeson,et al.  Thoracic computed tomography in patients with suspected malignant pleural effusions. , 2001, Clinical radiology.

[15]  R. Davies,et al.  Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial , 2003, The Lancet.

[16]  Chin-Pyng Wu,et al.  Echogenic swirling pattern as a predictor of malignant pleural effusions in patients with malignancies. , 2004, Chest.

[17]  R. Louis,et al.  Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging. , 2004, Chest.

[18]  J. M. Porcel,et al.  Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. , 2004, Chest.

[19]  S. Sahn,et al.  Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer. , 2004, Chest.

[20]  R. Dixit,et al.  Intrapleural streptokinase in multiloculated malignant pleural effusion. , 2004, The Indian journal of chest diseases & allied sciences.

[21]  Fergus V Gleeson,et al.  Radiology in pleural disease: State of the art , 2004, Respirology.

[22]  S. Mercadante,et al.  Video-thoracoscopic surgical pleurodesis in the management of malignant pleural effusion: the importance of an early intervention. , 2005, Journal of pain and symptom management.

[23]  F. Gleeson,et al.  Imaging of pleural disease. , 2006, Clinics in chest medicine.

[24]  A. Tremblay,et al.  Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. , 2005, Chest.

[25]  N. Ordóñez What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. , 2007, Human pathology.

[26]  M. Noppen,et al.  Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study , 2007, The Lancet.

[27]  J. M. Porcel,et al.  Prognostic significance of pleural fluid data in patients with malignant effusion. , 2008, European journal of internal medicine.

[28]  F. Gleeson,et al.  Thoracic ultrasound in the diagnosis of malignant pleural effusion , 2008, Thorax.

[29]  J. Heffner,et al.  Recent advances in the diagnosis and management of malignant pleural effusions. , 2008, Mayo Clinic proceedings.

[30]  W. Su,et al.  Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control. , 2009, Lung cancer.

[31]  M. Narasimhan,et al.  Pleural Ultrasonography , 2010 .

[32]  M. Raza Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010 , 2011 .

[33]  E. Duhig,et al.  Diagnostic molecular biomarkers for malignant pleural effusions. , 2011, Future oncology.

[34]  R. Davies,et al.  Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. , 2012, JAMA.

[35]  J. Kastelik,et al.  Management of Malignant Pleural Effusion , 2013, Lung.

[36]  H. Colt,et al.  Pleuroscopy in 2013. , 2013, Clinics in chest medicine.

[37]  D. Sterman,et al.  Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies. , 2013, Clinics in chest medicine.

[38]  J. Porcel Pleural fluid biomarkers: beyond the Light criteria. , 2013, Clinics in chest medicine.

[39]  F. Gleeson,et al.  Role of CT in assessing pleural malignancy prior to thoracoscopy , 2012, Thorax.

[40]  A. Fernández-Villar,et al.  Management of malignant pleural effusion by an indwelling pleural catheter: A cost-efficiency analysis , 2015, Annals of thoracic medicine.

[41]  J. M. Porcel,et al.  Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis. , 2015, Chest.